IP Library › Patent Application 11839985
Patent Application
App. No. 11/839,985

NMDA Receptor Antagonist Formulation With Reduced Neurotoxicity

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/839,985
Abstract

The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.

Claims (7)

1 . A spray device for intranasal delivery of a pharmaceutical composition, wherein the spray device contains a pharmaceutical composition comprising an aqueous solution of about 10% ketamine hydrochloride and about 0.001% to about 0.2% benzalkonium chloride, wherein the composition does not cause any significant neurotoxicity, and wherein the level of neurotoxicity is comparable to sterile water when administered.

2 . The spray device of claim 1 , wherein the pharmaceutical composition further comprises a suitable carrier selected from the group consisting of water, saline, bicarbonate, sucrose and mixtures thereof.

3 . A spray device for intranasal delivery of a pharmaceutical composition, wherein the spray device contains a pharmaceutical composition comprising an aqueous solution of about 10% ketamine hydrochloride and about 0.002% benzalkonium chloride, wherein the composition does not cause any significant neurotoxicity, and wherein the level of neurotoxicity is comparable to sterile water when administered.

4 . A spray device for intranasal delivery of a pharmaceutical composition, wherein the spray device contains a pharmaceutical composition comprising an aqueous solution of about 0.01 mg/kg to about 1 mg/kg ketamine hydrochloride and about 0.001% to about 0.2% per unit dose benzalkonium chloride, wherein the composition does not cause any significant neurotoxicity, and wherein the level of neurotoxicity is comparable to sterile water when administered.

5 . The spray device of claim 4 , wherein the pharmaceutical composition further comprises a suitable carrier selected from the group consisting of water, saline, bicarbonate, sucrose and mixtures thereof.

6 . The spray device of claim 4 , wherein the pharmaceutical composition is administered nasally with 1 to 5 sprays of the device.

7 . The spray device of claim 6 , wherein the pharmaceutical composition is administered nasally with 2 sprays of the device.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2012
From: JAVELIN PHARMACEUTICALS, INC.
To: WEG, STUART L.
Reel/Frame 028689/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2012
From: INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
To: JAVELIN PHARMACEUTICALS, INC.
Reel/Frame 028688/0575 →
SECURITY AGREEMENT Recorded Apr 20, 2010
From: INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
To: HOSPIRA, INC.
Reel/Frame 024252/0650 →
RELEASE OF SECURITY INTEREST Recorded Apr 20, 2010
From: MYRIAD PHARMACEUTICALS, INC.
To: INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
Reel/Frame 024252/0658 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE IDENTIFIED IN THE RECORDATION OF SECURITY AGREEMENT PREVIOUSLY RECORDED ON REEL 023698 FRAME 0285. ASSIGNOR(S) HEREBY CONFIRMS THE GRANT OF A SECURITY INTEREST IN ITS TITLE AND INTEREST IN PATENT APPLICATIONS/PATENT IDENTIFIED IN THE AGREEMENT. Recorded Apr 9, 2010
From: INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
To: MYRIAD PHARMACEUTICALS, INC.
Reel/Frame 024211/0088 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2009
From: INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
To: MYRIAD PHARMACEUTICALS, INC.
Reel/Frame 023698/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2007
From: MERMELSTEIN, FRED H.; ALBIN, RANDI
To: INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
Reel/Frame 020137/0075 →